T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays.

Abstract

We investigated the ability of bispecific anti-T-cell receptor x anti-tumor antibodies, destined for the study of T-cell retargeting in a rat colon carcinoma model, to enhance tumor neutralization by polyclonally activated CD8+ T lymphocytes in hepatic subcapsular Winn type assays against syngeneic CC531 colon carcinoma cells. Attempts to improve on initially unsatisfactory results were guided by a 3-day in vitro cocultivation assay, demonstrating that recombinant IL-2 (rIL-2) at concentrations as low as 1 U/ml would promote tumor neutralization by retargeted effector cells. Accordingly, we found that a nontoxic regimen of rIL-2 administration, 200,000 U subcutaneously every 8 h for 3 days, strongly enhanced natural killer-like as well as retargeted anti-tumor activity in Winn assays and enabled retargeted effector cells to prevent tumor growth in the majority of animals. These results back up and direct future attempts to treat established tumor lesions.

Statistics

050100150'96'98'00'02'04'06'08'10'12'14'16
Citations per Year

129 Citations

Semantic Scholar estimates that this publication has 129 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Beun1993TcellRU, title={T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays.}, author={G D Beun and Cornelis J. H. van de Velde and Gertjan J. Fleuren and Alexander M. M. Eggermont}, journal={Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy}, year={1993}, volume={14 1}, pages={11-5} }